American Journal of Cancer Prevention:

Home » Journal » AJCP » Archive » Volume 2, Issue 1

Article

Association between HPV and Head and Neck Cancer: Differences in Understanding among Three Distinct Populations

1Department of Otolaryngology Head and Neck Surgery, Emory University School of Medicine, Atlanta, GA 30308

2Massachusetts Eye and Ear Infirmary, Boston, MA 02114

3Oglethorpe University, Atlanta, GA 30319


American Journal of Cancer Prevention. 2014, 2(1), 14-19
DOI: 10.12691/ajcp-2-1-5
Copyright © 2014 Science and Education Publishing

Cite this paper:
Laura J. White, Francis X. Creighton Jr, Justin C. Wise, Edie R. Hapner. Association between HPV and Head and Neck Cancer: Differences in Understanding among Three Distinct Populations. American Journal of Cancer Prevention. 2014; 2(1):14-19. doi: 10.12691/ajcp-2-1-5.

Correspondence to: Edie  R. Hapner, Department of Otolaryngology Head and Neck Surgery, Emory University School of Medicine, Atlanta, GA 30308. Email: ehapner@emory.edu

Abstract

The aim of this study is to compare the knowledge of the relationship between HPV and head and neck cancer (HNCA) in three unique populations: general public at a sporting event, undergraduates, and medical students, and to compare the frequency that a healthcare provider has discussed the topics of cervical cancer and HNCA amongst these populations. A one-way between subjects design was used to evaluate participants at a community based head and neck cancer screening, and students in individual classrooms. A28-item questionnaire was administered to 491 NASCAR race attendees, 186 undergraduate students, and 158 medical students. The survey assessed their knowledge of the relationship between HPV and HNCA using a Likert scale. The survey also assessed the level of information disseminated by healthcare providers regarding HPV and HNCA. NASCAR attendees evidenced significantly (p < .001, η2 = .10) lower levels of knowledge of the relationship between HPV and cervical cancer than college or medical students. NASCAR attendees evidenced significantly (p < .001, η2 = .02) lower levels of knowledge of the relationship between HPV and HNCA. NASCAR attendees reported significantly (p < .001, η2 = .10) more frequent discussions with health care providers regarding HNCA compared to college or medical students. Undergraduates and medical students reported significantly (p < .001, η2 = .02) more frequent discussions with health care providers regarding HPV than NASCAR attendees. Results demonstrated group differences in knowledge between the relationship of HPV and cervical cancer and HPV and HNCA. All groups were more aware of HPV’s association with cervical cancer than with HNCA.

Keywords

References

[[[[[[[[[[[[[[[
[[1]  Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal incidence in the United States. J Clin Oncol. 2001; 29(32);4294-4301.
 
[[2]  Ernster JA, Sciotto CG, O’Brien MM, et al. Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus. Laryngoscope. 2007; 117:2115-2128.
 
[[3]  Rogers SN, Shreya VV, Lowe D. Reasons for delayed presentation in oral and oropharyngeal cancer: the patients perspective. Brit J Oral Max Surg. 2011;49(5):349-353.
 
[[4]  Attner P, Nasman A, Du J, et al. Survival in patients with human papillomavirus positive tonsillar cancer in relation to treatment. Int J Cancer. 2012; 131:1124-1130.
 
[[5]  White LJ, Chin-Quee AL, Berg CJ, et al. Differences in head and neck cancer risk perception between smoking and non-smoking NASCAR attendees. Otolaryngol Head Neck Surg. 2012;147:63-8.
 
Show More References
[6]  Smith, EM, Ritchie JM, Summersgill KF, et al. Age, sexual behavior, and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 2004;108:766-772.
 
[7]  Schwartz SM, Daling JR, Doody DR, et al. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst. 1998;90:1626-1636.
 
[8]  D’Souza G, Agrawal Y, Hapern J, et al. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Disease. 2009; 199:1263-1269.
 
[9]  Hariri S, Unger ER, Sternberg M, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survey, 2003-2006. J Infect Dis. 2011; 204(4):566-573.
 
[10]  Centers for Disease Control and Prevention. 2010 Sexually Transmitted Diseases Surveillance. http://www.cdc.gov/std/stats10/other.htm, accessed August 10, 2012.
 
[11]  Gerend MA, Shepherd JE. Correlates of HPV knowledge in the Era of HPV vaccination: A study of unvaccinated young adult women. Women Health. 2011; 51(1):25-40.
 
[12]  Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices. Grading of recommendations, assessment, development, and evaluation for HPV vaccine in males. MMWR. 2011; 60:1705-8.
 
[13]  Tiro JA, Meissner, HI, Kobrin S, Chollette V. What do women in the U.S. know about Human Papillomavirus and cervical cancer? Cancer Epidemio Biomarkers Prev. 2007; 16:288-294.
 
[14]  Wolf AMD, Becker DM. Cancer screening and informed patient discussions. Arch Intern Med. 1996: 156(10):1069-1072.
 
[15]  Mohyuddin N, Langerman A, LeHew C, et al. Knowledge of head and neck cancer among medical students at 2 Chicago Universities. Arch Otolaryngol Head Neck Surg. 2008:134(12):1294-8.
 
[16]  Wu EC, Passy V, Armstrong WB. Preliminary evaluation of junior medical students’ comfort with performing the basic head and neck examination. Laryngoscope. 2011;121:1431-1435.
 
[17]  Ferullo A, Silk H, Savageau JA. Teaching oral health in US medical Schools: Results of a national survey. Acad Med. 2011; 86:226-230.
 
[18]  Park ER, Ostroff JS, Rakowski W, et al. Risk perceptions among participants undergoing lung cancer screening: baseline results from the National Lung Screening Trial. Ann Behav Med. 2009; 37(3):268-79.
 
[19]  Viscusi, WK. Age variations in risk perceptions and smoking decisions. Rev Econ Statist. 1991;73:577-588.
 
[20]  Viscusi, WK. Do smokers underestimate risk? J Polit Economy. 1990;98:1253-1269.
 
Show Less References

Article

Knowledge and Practice on Oral Care among the Patients Receiving Chemotherapy

1Kathmandu University School of Medical Sciences, Dhulikhel, Kavre

2Emergency Department, Shahid Gangalal National Heart Centre, Kathmandu


American Journal of Cancer Prevention. 2014, 2(1), 9-13
DOI: 10.12691/ajcp-2-1-4
Copyright © 2014 Science and Education Publishing

Cite this paper:
Acharya Radha, Ojha Namrata. Knowledge and Practice on Oral Care among the Patients Receiving Chemotherapy. American Journal of Cancer Prevention. 2014; 2(1):9-13. doi: 10.12691/ajcp-2-1-4.

Correspondence to: Acharya  Radha, Kathmandu University School of Medical Sciences, Dhulikhel, Kavre. Email: radhapnd@yahoo.com

Abstract

Changes to the oral cavity arising from malignant disease, treatment and other co-morbidity factors can have a profound affect on the person with cancer, causing pain, discomfort, lack of nutrition, longer hospital stays, and in some situations sepsis and death. While it is recognized that caring for the mouth is an important aspect of cancer care, all too often this aspect of care may be overlooked until problems arise. This leads to needless distress and discomfort and in some cases serious clinical consequences. Oral and gastrointestinal mucositis can affect up to 100% of patients undergoing high-dose chemotherapy and hematopoietic stem cell transplantation. The aim of the study was to assess knowledge and practice on oral care among the patients receiving chemotherapy. This is descriptive cross-sectional study. A total of 102 respondents, visiting B.P. Koirala Memorial Cancer Hospital, Bharatpur Chitwan and who met eligible criteria were systematically sampled and interviewed face to face. Descriptive and inferential statistics were used for the analysis using the SPSS version 16.0. The duration of the study was one month i.e. June, 2010. The tool was developed after reviewing the related literatures. The knowledge on oral care was adequate among 23.4% of the respondents and 18.6% of the respondents had adequate practice receiving chemotherapy. Only 28.4% respondents had adequate knowledge. Among total respondents 60.7% of the respondents had adequate knowledge on the prevention of oral problems and 55.8% of the respondents had adequate knowledge on treatment of oral problems. Nurses were found as a main source of information on oral care. Thus, it was concluded that majority of the respondents had inadequate knowledge and practice on oral care. There was association between selected demographic (age and education). There was no association between family history of cancer and knowledge of respondents. Thus the study also concluded that adequate knowledge on oral care should be provided to the patients before undergoing chemotherapy.

Keywords

References

[[[[[[[
[[1]  Adams, R. (1996). Qualified nurse’s lack adequate knowledge related to oral health, resulting in adequate oral care of patients on medical wards, Journal of advanced, pp. 552-560.
 
[[2]  Sonis ST (2004). The Pathobiology of Mucositis. Nature Reviews Cancer. 4: 277-284. Stone R. & Hood (2007). mangement of oral mucositis at European transplantation centres, European journal of oncology nursing, pp. 53-59.
 
[[3]  Cawley, M. & Laura, M. (2005). Current Trends in Managing Oral Mucositis. Clinical Journal of Oncology Nursing, 9, (5): pp. 584-592.
 
[[4]  Dodds, MJ. et al. (2004). The Pathogenesis and Characterisation of Oral Mucositis Associated with Cancer Therapy. Oncology Nursing Forum. 31 (4): 5-11.
 
[[5]  Bellm, LA, Epstein, JB, Rose-Ped, A, et al. (2000). Patient Reports of Complications of Bone Marrow Transplantation. Support Care Cancer. 8: 33-39.
 
Show More References
[6]  Roberts, J. (2005). Developing an oral assessment and intervention tool for older people. British Journal of Nursing, 9 (17), pp. 1124-1127, Vol 6, No 1, pp. 28-32.
 
[7]  Eilers, J. (2004). Nursing interventions and supportive care for the prevention and treatment of oral mucositis associated with cancer treatment. Oncology Nursing Forum, 31, (4), pp. 13-23.
 
[8]  Djuric, M (2006). Mucositis prevention by improved dental care in acute leukemia patients. Support Care Cancer, pp. 137-146.
 
[9]  Stone J E & Hood H V (2007). Interventions for preventing oral mucositis for patients with cancer receiving treatment (Cochrane Review). The Cochrane Library, Issue 4, Chichester, UK: John Wiley & Sons.
 
[10]  Andersson, P., Westergren, A., Karlsson, S., Hallberg I. R., & Renvert, S. (2002). Oral health and nutritional status in a group of geriatric rehabilitation patients. Scandinavia Journal of Caring Science, Vol. 16, pp. 311-318.
 
[11]  Rubenstein, E, & Perterson, S. (2008). Clinical Practice Guidelines for the Prevention and Treatment of Cancer Therapy-Induced Oral and Gastrointestinal Mucositis. Supplement to Cancer, 100, (9) pp. 2026-2033.
 
[12]  Haghpanah, S. M., Aminni, M., Kherad K. (2006), knowledge and practice of patients with breast cancer patients about complication of chemotherapy, J Res Health Science, Vol 6, No 1, pp. 28-32.
 
Show Less References

Article

Human Papillomavirus Genotypes in the High Grade Preinvasive Cervical Lesions in Yaounde (Cameroon)

1Department of Pathology, Gynaeco-obstetrics and Pediatric Hospital, Yaoundé, Cameroon

2Department of Clinical Pathology, Geneva University Hopsital, Geneva, Switzerland


American Journal of Cancer Prevention. 2014, 2(1), 5-8
DOI: 10.12691/ajcp-2-1-3
Copyright © 2014 Science and Education Publishing

Cite this paper:
Zacharie Sando, Tomas McKee, Jean Claude Pache, Herman Kemajou, Olive Folem, Laura Rubbia–Brandt, Anderson Sama Doh. Human Papillomavirus Genotypes in the High Grade Preinvasive Cervical Lesions in Yaounde (Cameroon). American Journal of Cancer Prevention. 2014; 2(1):5-8. doi: 10.12691/ajcp-2-1-3.

Correspondence to: Zacharie  Sando, Department of Pathology, Gynaeco-obstetrics and Pediatric Hospital, Yaoundé, Cameroon. Email: sandozac@yahoo.fr

Abstract

The objectives of this study were to detect and determine the different genotypes of Human Papillomavirus (HPV) found in high-grade squamous preinvasive lesions of the uterine cervix of Cameroonian women. The age of the effected women was 28-55 years with 27 (69.3%) women between 34 and 40 years old. HPV genotyping was conducted on 37 endocervical secretions of women with high grade squamous intraepithelial lesions. HPV was found in 31 of the 37 women (83.8%); 9 different HPV genotypes were identified. The genotypes with high oncogenic potential were found in decreasing order of frequency as follows: 16, 18, 45, 33, 35 and 68. The frequency of strains found per patient ranged from 1 to 3. Genotypes 16 and 18 were single in 17 out of 31 patients. They were associated with other HPV genotypes in 4 out of 31 patients. In this study genotypes 16 and 18 are the most frequent genotypes encountered in high grade squamous preinvasive cervical lesions in Yaounde. This finding, if confirmed on a larger sample, portrays the potential effectiveness of HPV vaccines in the Cameroonian population as a preventive measure against cervical cancer. However, the position of genotype 45 is not negligible and should be confirmed on a large sample.

Keywords

References

[[[[[[[[[[[[[[[[[[
[[1]  Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJL et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. The lancet, 378 (9801):1461-1484, Oct. 2011.
 
[[2]  Enow-Orock GE, Essame-Oyono JL, Doh A. Cancer incidence in Yaoundé 2004-2008: Yaoundé Cancer Registry Technical Report.Yaoundé: National Cancer Control Program, Yaounde Cameroon, 2009.
 
[[3]  Sellors JW, Sankaranarayanan R. Colposcopie et traitement des néoplasies cervicales intraépithéliales: Manuel à l’usage des débutants. Centre international de recherche sur le cancer, Lyon France, 2004.
 
[[4]  Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. Humann papilloma virus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189 (1): 12-19, Sept. 1999.
 
[[5]  Didelot-Rousseau M-N, Nagot N, Costes-Martineau V, Ouedraogo A, Konate I, Weiss HA et al. Human papillomavirus genotypes distribution and cervical intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso. Br J Cancer, 95 (3): 355-362, Aug. 2006.
 
Show More References
[6]  Ali-Risasi C, Praet M, Van Renterghem L, Zinga-Ilunga B, Sengeyi D, Lokomba V et al. Human Papilloma virus genotypic Profile in Kinshasa, Democratic Republic of Congo: implications for vaccination. Med Trop, 68 (6): 617-20, Dec. 2008.
 
[7]  Salih MM, Safi ME, Hart K, Tobi K, Adam I. Genotypes of human papilloma virus in Sudanese women with cervical pathology, Infect Agent Cancer, 5: 26, Dec. 2010.
 
[8]  Ciapponi A, Bardach A, Glujovsky D, Gibbons L, Picconi MA. Type-specific HPV prevalence in cervical cancer and high-grade lesions in Latin America and the Caribbean: systematic review and meta-analysis. PLoS One 6 (10): e25493. Epub 2011 Oct. 4.
 
[9]  Wentzensen N, Schiffman M, Dunn T, Zuna RE, Gold MA, Allen RA et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer, 125 (9): 2151-8, Nov. 2009.
 
[10]  Kuypers JM, C. W. Critchlow CW, Gravitt PE, Vernon DA, Sayer JB, Manos MM et al., Comparison of dot filter hybridization, southern transfer hybridization, and polymerase chain reaction amplification for diagnosis of anal human papillomavirus infection. J Clin Microbiol, 31 (4): 1003-6, Apr. 1993.
 
[11]  Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method, J Clin Microbiol, 36 (10): 3020-7, Oct. 1998.
 
[12]  Wamai RG, Ayissi CA, Oduwo GO, Perlman S, Welty E, Manga S et al. Assessing the effectiveness of a community-based sensitization strategy in creating awareness about HPV, cervical cancer and HPV vaccine among parents in North West Cameroon. J Community Health, 37 (5): 917-26, Oct. 2012.
 
[13]  Ayissi CA, Wamai RG, Oduwo GO, Perlman S, Welty E, Welty T et al. acceptability and uptake of human papilloma virus vaccine among Cameroonian school-attending female adolescents. J Community Health, 37 (6): 1127-35, Dec. 2012.
 
[14]  McCarey C, Pirek D, Tebeu PM, Boulvain M, Doh AS, Petignat P. Awareness of HPV and cervical cancer prevention among Cameroonian healthcare workers. BMC Womens Health, 11: 45, Oct. 2011.
 
[15]  Berner A, Hassel SB, Tebeu PM, Untiet S, Kengne-Fosso G, Navarria I et al. Human Papillomavirus Self-Sampling in Cameroon: Women's Uncertainties Over the Reliability of the Method Are Barriers to Acceptance. J Low Genit Tract Dis, 17 (3): 235-41, Jul. 2013.
 
[16]  Hwang HS, Park M, Lee SY, Kwon KH, Pang MG. Distribution and Prevalence of Human Papillomavirus Genotypes in Routine Pap Smear of 2470 Korean Women Determined by DNA chip. Cancer Epidemiol Biomarkers Prev, 13 (12): 2153-56, Dec. 2004.
 
[17]  Stevens MP, Tabrizi SN, Quinn M, Garland SM. Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia. Int J Gynecol Cancer, 16 (3): 1017-1024, May-Jun. 2006.
 
[18]  Lindemann MLM, Sanchez JMC, Chacon JA, Itziar S, Diaz E, Rubio MD et al. Prevalence and distribution of high-risk genotype of HPV in women with severe cervical lesion in Madrid, Spain: importance of detecting genotype 16 and other high-risk genotypes. Adv Prev Med 2011; 2011: 269468.
 
[19]  Winkelstein WJ. Smoking and cervical cancer-current status: a review. Am J Epidemiol, 131 (6): 945-957, Jun. 1990.
 
[20]  Clifford GM, Smith JS, Plummer M, Muňoz N. & Franceschi S. Human papilloma virus types in invasive cervical cancer worldwide: a meta analysis. Br J Cancer, 88 (1): 63-73, Jan. 2003.
 
[21]  Muňoz N, Bosh F X, Casttellague X, de Sanjose S, Hammouda D, Shah K V & al. Against which human papilloma virus types shall we vaccinate and screen? The international perspective. Int J Cancer; 111 (2): 278-285, Aug. 2004.
 
[22]  Chen CA, Liuy HH, Chou CY, Ho CM, Twu NF, Kan YY et al. The distribution and differential risks of human papilloma virus genotypes in cervical pre invasive lesions: a Taiwan Cooperative Oncologic Group Study. Int J Gynecol Cancer, 16 (5): 1801-1808, Sept-Oct. 2006.
 
[23]  Desruisseau AJ, Schmidt-Drimminger D, Welty E. Epidemiology of HPV in HIV-Positive and HIV-Negative Fertile Women in Cameroon, West Africa. Inf Dis Obstet Gynecol vol 2009 (2009). Article ID 810596, 6 pages.
 
Show Less References

Article

A Brief Note on the Limitation of Treatment Planning in Proton Therapy

1Department of Medical Physics, ProCure Proton Therapy Center, Oklahoma City, OK, USA


American Journal of Cancer Prevention. 2014, 2(1), 4-4
DOI: 10.12691/ajcp-2-1-2
Copyright © 2014 Science and Education Publishing

Cite this paper:
Suresh Rana. A Brief Note on the Limitation of Treatment Planning in Proton Therapy. American Journal of Cancer Prevention. 2014; 2(1):4-4. doi: 10.12691/ajcp-2-1-2.

Correspondence to: Suresh  Rana, Department of Medical Physics, ProCure Proton Therapy Center, Oklahoma City, OK, USA. Email: suresh.rana@gmail.com

Abstract

References

[[[
[[1]  http://ptcog.web.psi.ch/ptcentres.html [Accessed on January 12, 2014].
 
[[2]  Wilson RR. Radiological use of fast protons. Radiology 1946; 47: 487-491.
 
[[3]  Ulmer W. Notes of the editorial board on the role of medical physics in radiotherapy. Int J Cancer Ther Oncol 2013;1(1):01014.
 
[[4]  Zheng Y, Ramirez E, Mascia A, Ding X, Okoth B, Zeidan O, Hsi W, Harris B, Schreuder AN, Keole S. Commissioning of output factors for uniform scanning proton beams. Med Phys. 2011;38(4):2299-306.
 
[[5]  Hong L, Goitein M, Bucciolini M, Comiskey R, Gottschalk B, Rosenthal S, Serago C, Urie M. A pencil beam algorithm for proton dose calculations. Phys Med Biol. 1996; 41(8):1305-30.
 
Show More References
[6]  Rana S, Zeidan O, Ramirez E, Rains M, Gao J, Zheng Y. Measurements of lateral penumbra for uniform scanning proton beams under various beam delivery conditions and comparison to the XiO treatment planning system. Med Phys 2013; 40:091708
 
[7]  Rana S, Singh H. Impact of heterogeneities on lateral penumbra in uniform scanning proton therapy. Int J Cancer Ther Oncol 2013; 1(2):01026.
 
[8]  Islam MR. Secondary neutrons issue in proton radiotherapy-a brief report. Int J Cancer Ther Oncol 2014; 2(1):02017.
 
Show Less References

Article

A note on the Radiation Treatment Planning for the Prostate Cancer

1Xinjiang Medical University, Xinjiang, China


American Journal of Cancer Prevention. 2014, 2(1), 1-3
DOI: 10.12691/ajcp-2-1-1
Copyright © 2014 Science and Education Publishing

Cite this paper:
Robert Shi. A note on the Radiation Treatment Planning for the Prostate Cancer. American Journal of Cancer Prevention. 2014; 2(1):1-3. doi: 10.12691/ajcp-2-1-1.

Correspondence to: Robert  Shi, Xinjiang Medical University, Xinjiang, China. Email: rshi01293@yahoo.com

Abstract

Radiation therapy has been one of the major treatment modalities for the prostate cancer over the past few decades. Treatment planning system (TPS) is an integral component in radiation therapy in order to ensure the accurate estimation of radiation dose to the tumor. However, due to the variability in optimization techniques and beam modeling among various TPS, the current literature on radiation treatment planning have shown disagreement on the dosimetric findings, especially for the intensity modulated radiation therapy (IMRT) and volumetric modulated radiation therapy (VMAT). This may create a confusion for the cancer centers who are debating whether to implement IMRT or VMAT as the primary treatment modality for the cancer treatment in their institution. The purpose of this article is to provide the brief review on the IMRT and VMAT for the prostate cancer treatment.

Keywords

References

[[[[[[[[[[[[[[[[[
[[1]  Otto K. Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys 2008; 35: 310-17.
 
[[2]  Kjaer-Kristoffersen F, Ohlhues L, Medin J, Korreman S. RapidArc volumetric modulated therapy planning for prostate cancer patients. Acta Oncol. 2009; 48 (2): 227-32.
 
[[3]  Zhang P, Happersett L, Hunt M, Jackson A, Zelefsky M, Mageras G. Volumetric modulated arc therapy: planning and evaluation for prostate cancer cases. Int J Radiat Oncol Biol Phys. 2010 Apr; 76 (5): 1456-62.
 
[[4]  Rao M, Yang W, Chen F, Sheng K, Ye J, Mehta V, Shepard D, Cao D. Comparison of Elekta VMAT with helical tomotherapy and fixed field IMRT: plan quality, delivery efficiency and accuracy. Med Phys. 2010 Mar; 37 (3): 1350-9.
 
[[5]  Sze HC, Lee MC, Hung WM, Yau TK, Lee AW. RapidArc radiotherapy planning for prostate cancer: Single-arc and double-arc techniques vs. intensity-modulated radiotherapy. Med Dosim 2012; 37: 87-91.
 
Show More References
[6]  Herman TF, Schnell E, Young J, Hildebrand K, Algan Ö, Syzek E, Herman T, Ahmad S. Dosimetric comparison between IMRT delivery modes: Step-and-shoot, sliding window, and volumetric modulated arc therapy-for whole pelvis radiation therapy of intermediate-to-high risk prostate adenocarcinoma. J Med Phys 2013; 38: 165-72.
 
[7]  Tsai CL, Wu JK, Chao HL, Tsai YC, Cheng JC. Treatment and dosimetric advantages between VMAT, IMRT, and helical tomotherapy in prostate cancer. Med Dosim. 2011 Autumn; 36 (3): 264-71.
 
[8]  Wolff D, Stieler F, Welzel G, Lorenz F, Abo-Madyan Y, Mai S, Herskind C, Polednik M, Steil V, Wenz F, Lohr F. Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer. Radiother Oncol. 2009; 93 (2): 226-33.
 
[9]  Yoo S, Wu QJ, Lee WR, Yin FF. Radiotherapy treatment plans with RapidArc for prostate cancer involving seminal vesicles and lymph nodes. Int J Radiat Oncol Biol Phys. 2010 Mar 1; 76 (3): 935-42.
 
[10]  Chow JC, Jiang R. Prostate volumetric-modulated arc therapy: dosimetry and radiobiological model variation between the single-arc and double-arc technique. J Appl Clin Med Phys. 2013 May 6; 14 (3): 4053.
 
[11]  Rana SB, Cheng C. Investigating VMAT planning technique to reduce rectal and bladder dose in prostate cancer treatment plans. Clin Cancer Investig J 2013; 2: 212-7.
 
[12]  Rana S, Cheng C. Feasibility of the partial-single arc technique in RapidArc planning for prostate cancer treatment. Chin J Cancer. 2013; 32 (10): 546-52.
 
[13]  Lu L. Dose calculation algorithms in external beam photon radiation therapy. Int J Cancer Ther Oncol 2013; 1 (2): 01025.
 
[14]  Oyewale S. Dose prediction accuracy of collapsed cone convolution superposition algorithm in a multi-layer inhomogenous phantom. Int J Cancer Ther Oncol 2013; 1 (1): 01016.
 
[15]  Rana S, Rogers K. Dosimetric evaluation of Acuros XB dose calculation algorithm with measurements in predicting doses beyond different air gap thickness for smaller and larger field sizes. J Med Phys. 2013; 38 (1): 9-14.
 
[16]  Pokharel S. Dosimetric impact of mixed-energy volumetric modulated arc therapy plans for high-risk prostate cancer. Int J Cancer Ther Oncol 2013; 1 (1): 01011.
 
[17]  Park JM, Choi CH, Ha SW, Ye SJ. The dosimetric effect of mixed-energy IMRT plans for prostate cancer. J Appl Clin Med Phys 2011; 12: 3563.
 
[18]  Hawke S, Torrance A, Tremethick L. Evaluation of planned dosimetry when beam energies are substituted for a fraction of the treatment course. Int J Cancer Ther Oncol 2013; 1 (2): 01014.
 
[19]  Kry SF, Salehpour M, Followill DS, et. al. The calculated risk of fatal secondary malignancies from intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 2005; 62: 1195-203.
 
[20]  Mavroidis P. Clinical implementation of radiobiological measures in treatment planning. Why has it taken so long? Int J Cancer Ther Oncol 2013; 1 (1): 01019.
 
[21]  Sanfilippo N, Hardee ME, Wallach J. Review of chemoradiotherapy for high-risk prostate cancer. Rev Recent Clin Trials. 2011 Jan; 6 (1): 64-8.
 
[22]  Saha A, Chattopadhyay S. Assessment of pulmonary toxicities in breast cancer patients undergoing treatment with anthracycline and taxane based chemotherapy and radiotherapy-a prospective study. Int J Cancer Ther Oncol 2013; 1 (2): 01021.
 
Show Less References
comments powered by Disqus